MTEX · Mannatech Inc - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · MTEX

1Y 3Y 5Y Max

Annual Quarterly

Income Statement

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$108.04M	$117.87M	$131.96M	$137.21M	$159.76M	$151.41M
Cost of Revenue	$27.08M	$26.41M	$29.09M	$33.06M	$34.15M	$35.51M
Gross Profit	$80.96M	$91.46M	$102.86M	$104.15M	$125.61M	$115.90M
R&D	$800.0K	$700.0K	$800.0K	$1.00M	$1.20M	$800.0K
SG&A	$41.72M	$41.72M	$48.61M	$27.47M	$29.43M	$27.84M
Total Operating Expenses	$81.39M	$90.03M	$103.83M	$104.55M	$116.56M	$111.41M
D&A	$1.09M	$1.53M	$1.63M	$1.63M	$1.72M	$1.99M
Operating Income	($426.0K)	$1.43M	($964.0K)	($405.0K)	$9.05M	$4.49M
Interest Expense	$279.0K	-	-	-	-	-
Income Tax	$12.32M	$1.25M	$1.11M	$4.01M	($950.0K)	($536.0K)
Net Income	($15.21M)	$2.49M	($2.24M)	($4.49M)	$9.84M	$6.26M
EPS - Basic	($8.00)	$1.32	($1.20)	($2.35)	$4.95	$2.80
EPS - Diluted	($8.00)	$1.32	($1.20)	($2.35)	$4.71	$2.77

Balance Sheet

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Cash & Equivalents	$6.18M	$11.40M	$7.73M	$13.78M	$24.18M	$22.21M
Accounts Receivable	$1.0K	$19.0K	$91.0K	$218.0K	$90.0K	$186.0K
Inventory	$10.12M	$10.40M	$14.54M	$14.73M	$12.02M	$12.83M
Accounts Payable	$2.41M	$2.07M	$4.01M	$4.36M	$3.97M	$4.80M
Current Assets	$20.58M	$26.12M	$27.66M	$34.95M	$42.84M	$42.48M
Total Assets	$29.99M	$36.06M	$41.21M	$49.13M	$59.63M	$65.34M
Current Liabilities	$18.73M	$20.90M	$25.78M	$29.84M	$30.10M	$31.99M
Long-term Debt	$2.75M	-	-	-	-	-
Total Liabilities	$35.22M	$27.44M	$30.72M	$34.95M	$35.21M	$39.36M
Stockholders' Equity	($5.22M)	$8.61M	$10.48M	$14.18M	$24.41M	$25.97M
Retained Earnings	($14.02M)	$1.19M	($1.30M)	$1.69M	$7.71M	$2.21M

Cash Flow

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Operating Cash Flow	($2.96M)	$2.26M	($2.37M)	($2.60M)	$10.77M	$6.03M
Investing Cash Flow	($1.35M)	($285.0K)	($747.0K)	($1.06M)	($650.0K)	($947.0K)
Financing Cash Flow	($561.0K)	$1.96M	($1.90M)	($4.33M)	($9.29M)	($9.92M)
CapEx	$1.35M	$297.0K	$748.0K	$1.06M	$650.0K	$949.0K
Free Cash Flow	($4.32M)	$1.96M	($3.12M)	($3.66M)	$10.12M	$5.08M

Ratios

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Profitability
Gross margin	74.9%	77.6%	78.0%	75.9%	78.6%	76.5%
Operating margin	-0.4%	1.2%	-0.7%	-0.3%	5.7%	3.0%
EBITDA margin	0.6%	2.5%	0.5%	0.9%	6.7%	4.3%
Net margin	-14.1%	2.1%	-1.7%	-3.3%	6.2%	4.1%
Free cash flow margin	-4.0%	1.7%	-2.4%	-2.7%	6.3%	3.4%
FCF / Net income	0.28	0.79	1.39	0.82	1.03	0.81
R&D / Revenue	0.7%	0.6%	0.6%	0.7%	0.8%	0.5%
SG&A / Revenue	38.6%	35.4%	36.8%	20.0%	18.4%	18.4%
Effective tax rate	-	33.4%	-	-	-10.7%	-9.4%
Return on assets	-50.7%	6.9%	-5.4%	-9.1%	16.5%	9.6%
Return on equity	291.3%	28.9%	-21.4%	-31.7%	40.3%	24.1%
Return on invested capital	-	-	-	-	-	-
Liquidity
Current ratio	1.10	1.25	1.07	1.17	1.42	1.33
Quick ratio	0.56	0.75	0.51	0.68	1.02	0.93
Cash ratio	0.33	0.55	0.30	0.46	0.80	0.69
Leverage
Debt / Equity	-0.53	-	-	-	-	-
Debt / Assets	0.09	-	-	-	-	-
Debt / EBITDA	4.13	-	-	-	-	-
Interest coverage	-1.5x	-	-	-	-	-
Equity multiplier	-5.74	4.19	3.93	3.47	2.44	2.52
Liabilities / Assets	1.17	0.76	0.75	0.71	0.59	0.60
Efficiency
Asset turnover	3.60	3.27	3.20	2.79	2.68	2.32
Inventory turnover	2.67	2.54	2.00	2.25	2.84	2.77
Days sales outstanding	0d	0d	0d	1d	0d	0d
Days inventory outstanding	136d	144d	182d	163d	128d	132d
Days payable outstanding	32d	29d	50d	48d	42d	49d
Cash conversion cycle	104d	115d	132d	115d	86d	83d
Valuation
P / E	-	10.2x	-	-	8.1x	6.7x
P / B	-	2.9x	1.4x	2.4x	3.3x	1.6x
P / S	0.1x	0.2x	0.1x	0.2x	0.5x	0.3x
EV / EBITDA	18.4x	4.7x	11.1x	16.7x	5.2x	3.1x
Growth
Revenue growth (YoY)	-8.3%	-10.7%	-3.8%	-14.1%	5.5%	-12.8%
Revenue CAGR (3y)	-7.7%	-9.6%	-4.5%	-7.5%	-2.7%	-5.0%
Revenue CAGR (5y)	-6.5%	-7.4%	-5.3%	-4.9%	-2.4%	-3.4%
Gross profit growth (YoY)	-11.5%	-11.1%	-1.2%	-17.1%	8.4%	-8.1%
Operating income growth (YoY)	-	-	-138.0%	-	101.5%	-30.2%
Net income growth (YoY)	-	-	50.1%	-	57.2%	90.4%
EPS growth (YoY)	-	-	48.9%	-	70.0%	105.2%
EPS CAGR (3y)	-	-34.6%	-	-	-	-
EPS CAGR (5y)	-	-0.4%	-	-	-	5.3%
FCF growth (YoY)	-	-	14.9%	-	99.3%	-
FCF CAGR (5y)	-	-	-	-	-	16.1%
Book value growth (YoY)	-	-17.8%	-26.0%	-41.9%	-6.0%	-4.8%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-12-31.

Product / service

$108.40M total

Product$106.00M · 97.8%

Product And Service Other$1.60M · 1.5%

Associate Fees$400.0K · 0.4%

Associate Service Fees$400.0K · 0.4%

Geographic

$206.90M total

Asia Pacific$66.40M · 32.1%

KR$43.70M · 21.1%

Americas$32.50M · 15.7%

US$22.40M · 10.8%

Asia Pacific Other$11.50M · 5.6%

CN$11.20M · 5.4%

Americas Other$10.10M · 4.9%

EMEA$9.10M · 4.4%

Stability scores

Altman Z′

FY 2025 · bankruptcy risk

3.14

Safe

Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.

Piotroski F-score

FY 2025 · 9-point quality

3/9

Weak

✗Net income positive
✗Operating cash flow positive
✗ROA improved YoY
✓Cash flow > net income
-Long-term debt decreased
✗Current ratio improved
✓No share dilution
✗Gross margin improved
✓Asset turnover improved

Peer comparison

Same SIC group: Medicinal Chemicals & Botanical Products

Company	Revenue (last FY)	Net margin	ROE
USNA	$925.26M	1.2%	2.0%
TRUL	$1.18B	-9.9%	-10.2%
CRON	$146.59M	-6.4%	-0.9%
CYAN	$24.21M	-13.2%	-36.1%
MNMD	-	-	-55.3%

Comparing MANNATECH INC against the 5 most active filers in the same SIC group.

Dividends

$0.00/share trailing 12 months

Ex-date	Per share
Jun 14, 2023	$0.2000
Mar 15, 2023	$0.2000
Dec 13, 2022	$0.2000
Sep 13, 2022	$0.2000
Jun 14, 2022	$0.2000
Mar 15, 2022	$0.2000
Dec 14, 2021	$1.7000
Sep 14, 2021	$0.2000
Jun 1, 2021	$0.1600
Mar 15, 2021	$0.1600
Dec 15, 2020	$1.1600
Sep 14, 2020	$0.1600
Jun 11, 2020	$0.1250
Mar 12, 2020	$0.1250
Dec 12, 2019	$0.1250
Sep 9, 2019	$0.1250
Jun 20, 2019	$0.1250
Mar 21, 2019	$0.1250
Dec 6, 2018	$0.5000
Sep 14, 2018	$0.5000
May 22, 2018	$0.1250
Mar 20, 2018	$0.1250
Dec 6, 2017	$0.1250
Sep 12, 2017	$0.1250